Insulet (NASDAQ:PODD) Raised to “Buy” at Wall Street Zen

Insulet (NASDAQ:PODD) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report issued on Friday.

Several other equities analysts have also recently issued reports on PODD. Oppenheimer boosted their target price on Insulet from $312.00 to $324.00 and gave the stock an “outperform” rating in a research report on Friday, May 9th. Barclays upped their price target on Insulet from $234.00 to $266.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 30th. Raymond James restated an “outperform” rating and issued a $360.00 price target (up previously from $328.00) on shares of Insulet in a report on Tuesday, May 27th. Stifel Nicolaus upped their price target on Insulet from $245.00 to $293.00 and gave the stock a “hold” rating in a report on Friday, February 21st. Finally, Wells Fargo & Company set a $322.00 price target on Insulet in a report on Monday, April 28th. Three analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat, Insulet has a consensus rating of “Moderate Buy” and a consensus price target of $318.41.

Insulet Stock Performance

NASDAQ PODD opened at $324.50 on Friday. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The business’s 50 day moving average is $276.61 and its two-hundred day moving average is $271.71. Insulet has a 12-month low of $172.07 and a 12-month high of $329.33. The stock has a market capitalization of $22.84 billion, a price-to-earnings ratio of 56.05, a PEG ratio of 3.62 and a beta of 1.26.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.81 by $0.21. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The company had revenue of $569.00 million for the quarter, compared to analysts’ expectations of $543.20 million. During the same quarter in the previous year, the firm posted $0.73 EPS. The firm’s quarterly revenue was up 28.8% on a year-over-year basis. Research analysts expect that Insulet will post 3.92 EPS for the current year.

Insider Activity at Insulet

In related news, SVP John W. Kapples sold 5,278 shares of the company’s stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total value of $1,680,884.66. Following the sale, the senior vice president now owns 23,180 shares of the company’s stock, valued at approximately $7,382,134.60. This represents a 18.55% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Wayne A.I. Frederick sold 1,825 shares of the company’s stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total value of $501,875.00. Following the completion of the sale, the director now directly owns 3,231 shares in the company, valued at approximately $888,525. The trade was a 36.10% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in PODD. Blue Trust Inc. lifted its stake in shares of Insulet by 117.3% during the 4th quarter. Blue Trust Inc. now owns 276 shares of the medical instruments supplier’s stock worth $72,000 after purchasing an additional 149 shares during the period. Swedbank AB lifted its stake in shares of Insulet by 152.9% during the 4th quarter. Swedbank AB now owns 53,688 shares of the medical instruments supplier’s stock worth $14,016,000 after purchasing an additional 32,456 shares during the period. Baader Bank Aktiengesellschaft purchased a new position in shares of Insulet during the 4th quarter worth $234,000. OLD National Bancorp IN purchased a new position in shares of Insulet during the 4th quarter worth $215,000. Finally, Mediolanum International Funds Ltd lifted its stake in shares of Insulet by 32.7% during the 4th quarter. Mediolanum International Funds Ltd now owns 8,890 shares of the medical instruments supplier’s stock worth $2,336,000 after purchasing an additional 2,189 shares during the period.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.